Neoadjuvant & adjuvant therapy recommendations: Neoadjuvant therapy may be considered in patients where there may be increased risk or morbidity with upfront resection or clinical suspicion of multi-organ involvement. At this time, we recommend adjuvant imatinib therapy for those with intermediate- to high-risk resected GIST based on stratification. The duration of therapy should be 3 years. We also recommend mutational analysis in those with resected GIST tumours. Those with non-imatinib-sensitive mutations should not receive adjuvant imatinib. Retrospective studies failed to show any benefit of 800 mg of imatinib in exon 9 GIST. Since insufficient data exist to recommend 800 mg of imatinib for those known to have an exon nine mutation, the discussion should be individualized based on tolerance and patient preference. 41